Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Myelodysplastic/myeloproliferative diseases
Stage/Subtype:  juvenile myelomonocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 39 for your search:
Start Over
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide after Donor Bone Marrow Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 6 months to 85
Trial IDs: J1151, NCI-2014-01339, CR00000875, NA_00048378, NA_00048378 / CIR00006178, NCI-2014-00310, NCT01342289
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 1825.00, NCI-2010-00230, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Busulfan, Cyclophosphamide, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Juvenile Myelomonocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: MT1999-20, NCI-2010-01703, 1999LS073, NCT00167219
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: 45 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who are Undergoing Umbilical Cord Blood Transplant
Phase: Phase II
Type: Treatment
Age: Under 65
Trial IDs: 2275.00, NCI-2010-00299, FHCRC-2275.00, IR-6800, NCT00796068
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, NCT00968630
Donor Stem Cell Transplant with Mismatched Donors and High-Dose Post-Transplant Cyclophosphamide in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0266, NCI-2011-03144, NCT01010217
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
Clofarabine, Busulfan and Fludarabine Phosphate Followed by Donor Stem Cell Transplant in Treating Young Patients With High Risk Hematological Malignancies or Hematological Disorders
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months to 30 years
Trial IDs: CC #110819, NCI-2012-00800, NCT01596699
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Chemotherapy before and after Donor Bone Marrow Transplant in Treating Younger Patients with Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: 6 months to 25 years
Trial IDs: J13161, NCI-2014-01899, NA_00091665, NA_00091665 / CIR00003493, NCT02120157
Cyclophosphamide, Fludarabine Phosphate, and Donor White Blood Cells Treating Patients With Hematologic Malignancies That Relapsed After a Previous Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: 1 and over
Trial IDs: MT2003-15, NCI-2010-01695, 2004LS006, NCT00303693, NCT00167180
T-cell Depleted Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 14-228, NCI-2015-00179, NCT02350777
Start Over